BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20483703)

  • 1. [Antiangionic drugs in soft tissue sarcoma].
    Salas S; Huynh T; Deville JL; Duffaud F
    Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Angiogenesis targeting in renal carcinomas].
    Pouessel D; Culine S
    Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
    English BC; Price DK; Figg WD
    Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis regulated by VEGF and its receptors and its clinical application.
    Shibuya M
    Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers].
    Bennis Y; Guillet B; Curti C; Pisano P
    Therapie; 2010; 65(2):95-105. PubMed ID: 20478241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
    Rini BI
    Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapy for breast cancer.
    Nielsen DL; Andersson M; Andersen JL; Kamby C
    Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
    Sessa C; Guibal A; Del Conte G; Rüegg C
    Nat Clin Pract Oncol; 2008 Jul; 5(7):378-91. PubMed ID: 18560389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    Quesada AR; Medina MA; Alba E
    Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
    Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract]   [Full Text] [Related]  

  • 18. [Renal cell carcinoma and antiangiogenic therapies].
    Pouessel D; Culine S; Verhoest G; Patard JJ
    Presse Med; 2008 Apr; 37(4 Pt 2):628-33. PubMed ID: 18035517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.